Key Information for ImmunoGen (IMGN) Investors

By Chris Stiles • Thursday, February 08 15:36 • Permanent Link

With gains of 5.7%, ImmunoGen was one of the winners on Wall Street today. Its shares are now trading at $31.23 and have logged a 0.0% daily outperformance of the S&P 500. Don't join the feeding frenzy before checking some basic facts about this stock:

ImmunoGen has moved 601.9% over the last year, and the S&P 500 logged a change of 22.4%
IMGN has an average analyst rating of hold and is 0.55% away from its mean target price of $31.06 per share
Its trailing earnings per share (EPS) is $-0.28
ImmunoGen has a trailing 12 month Price to Earnings (P/E) ratio of -111.5 while the S&P 500 average is 15.97
Its forward earnings per share (EPS) is $0.38 and its forward P/E ratio is 82.2
The company has a Price to Book (P/B) ratio of 15.2 in contrast to the S&P 500's average ratio of 2.95
ImmunoGen is part of the Health Care sector, which has an average P/E ratio of 30.21 and an average P/B of 4.08
The company has a free cash flow of $-133204376, which refers to the total sum of all its inflows and outflows of cash over the last quarter
ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.